Detalhe da pesquisa
1.
Development of a Tag/Catcher-mediated capsid virus-like particle vaccine presenting the conserved Neisseria gonorrhoeae SliC antigen that blocks human lysozyme.
Infect Immun;
91(12): e0024523, 2023 Dec 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37916806
2.
Seroprevalence of SARS-CoV-2 antibodies among children and adolescents recruited in a malariometric survey in north-eastern Tanzania July 2021.
BMC Infect Dis;
22(1): 846, 2022 Nov 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36371172
3.
Modified MHC Class II-Associated Invariant Chain Induces Increased Antibody Responses against Plasmodium falciparum Antigens after Adenoviral Vaccination.
J Immunol;
202(8): 2320-2331, 2019 04 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30833346
4.
An S1-Nanoparticle Vaccine Protects against SARS-CoV-2 Challenge in K18-hACE2 Mice.
J Virol;
96(14): e0084422, 2022 07 27.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35766489
5.
In vivo testing of novel vaccine prototypes against Actinobacillus pleuropneumoniae.
Vet Res;
49(1): 4, 2018 01 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29316978
6.
Identification and characterization of serovar-independent immunogens in Actinobacillus pleuropneumoniae.
Vet Res;
48(1): 74, 2017 11 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29122004
7.
Future Prospects for the Development of Cost-Effective Adenovirus Vaccines.
Int J Mol Sci;
18(4)2017 Mar 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28420073
8.
Quality control of microbiota metagenomics by k-mer analysis.
BMC Genomics;
16: 183, 2015 Mar 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25887914
9.
First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2.
Lancet Microbe;
4(3): e140-e148, 2023 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36681093
10.
Freeze-Drying of a Capsid Virus-like Particle-Based Platform Allows Stable Storage of Vaccines at Ambient Temperature.
Pharmaceutics;
14(6)2022 Jun 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35745873
11.
SARS-CoV-2 RBD-Specific Antibodies Induced Early in the Pandemic by Natural Infection and Vaccination Display Cross-Variant Binding and Inhibition.
Viruses;
14(9)2022 08 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36146667
12.
Site-Specific O-Glycosylation Analysis of SARS-CoV-2 Spike Protein Produced in Insect and Human Cells.
Viruses;
13(4)2021 03 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33806155
13.
Site-specific O-glycosylation analysis of SARS-CoV-2 spike protein produced in insect and human cells.
bioRxiv;
2021 Feb 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33564762
14.
Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants.
mBio;
12(5): e0181321, 2021 10 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34634927
15.
Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity.
Nat Commun;
12(1): 324, 2021 01 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33436573
16.
The potential of adenoviral vaccine vectors with altered antigen presentation capabilities.
Expert Rev Vaccines;
19(1): 25-41, 2020 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31889453
17.
Replication deficient human adenovirus vector serotype 19a/64: Immunogenicity in mice and female cynomolgus macaques.
Vaccine;
36(41): 6212-6222, 2018 10 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30190120